-

Sarepta Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following investor conferences in June:

  • Goldman Sachs 47th Annual Global Healthcare Conference
    Fireside chat: Monday, June 8, at 10:40 a.m. ET at the Loews Miami Beach Hotel in Miami Beach, Fla.
  • Oppenheimer CNS and Neuro-Muscular Summit
    Investor meetings: Wednesday, June 10, 2026 at The Bath Club in Miami Beach, Fla.

The presentation for the Goldman Sachs conference will be webcast live under the investor relations section of Sarepta’s website at https://investorrelations.sarepta.com/events-presentations and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases.

Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Contacts

Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com

Ryan Wong, 617-800-4112
rwong@sarepta.com

Tam Thornton, 617-803-3825
tthornton@sarepta.com

Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com

Sarepta Therapeutics, Inc.

NASDAQ:SRPT

Release Versions

Contacts

Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com

Ryan Wong, 617-800-4112
rwong@sarepta.com

Tam Thornton, 617-803-3825
tthornton@sarepta.com

Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com

More News From Sarepta Therapeutics, Inc.

Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, Sept. 14, at 8:30 a.m. ET. The presentation will be webcast live under the investor relations section of Sarepta’s website at https://investorrelations.sarepta.com/events-presentations and will be archived there f...

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2026. “As I begin my tenure as CEO, I am excited by the strength of Sarepta's foundation, the impact our therapies are having for patients, and the significant opportunities ahead,” said Michael Severino, MD, chief executive officer, Sarepta Therapeutics. “Our second quarter results, including $328.7 m...

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 28, 2026, that were previously approved by its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as amended, as a material inducement to employment to Michael Severino, M.D. as Chief Executive Officer of Sarepta. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). Dr. Se...
Back to Newsroom